Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

Supportive Care ◽

Metastatic Breast ◽

Epoetin Alfa ◽

Standard Chemotherapy ◽

Open Label ◽

Phase 3 ◽

Abstract P1-14-01: Final analysis of overall survival (OS) for the epoetin alfa (EPO) phase 3 study, EPO-ANE-3010, of EPO plus standard supportive care (SOC) versus SOC in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

10.1158/1538-7445.sabcs17-p1-14-01 ◽

2018 ◽

Author(s):

B Leyland-Jones ◽

I Bondarenko ◽

G Nemsadze ◽

V Smirnov ◽

I Litvin ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Supportive Care ◽

Metastatic Breast ◽

Final Analysis ◽

Epoetin Alfa ◽

Standard Chemotherapy ◽

Phase 3

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30702-6 ◽

2021 ◽

Vol 22 (3) ◽

pp. 351-360

Author(s):

Binghe Xu ◽

Min Yan ◽

Fei Ma ◽

Xichun Hu ◽

Jifeng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Randomised Controlled

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

First Line Treatment

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00184-2 ◽

2011 ◽

Vol 2011 ◽

pp. 117-118

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Randomised Study ◽

Versus Treatment

Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1049 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1049-1049 ◽

Cited By ~ 1

Author(s):

V. Dieras ◽

M. J. Kennedy ◽

P. Tresca ◽

M. E. Marty ◽

H. Burris ◽

...

Keyword(s):

Breast Cancer ◽

Dose Escalation ◽

Metastatic Breast ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

Investigational New Drugs ◽

10.1007/s10637-008-9166-8 ◽

2008 ◽

Vol 27 (2) ◽

pp. 166-172 ◽

Cited By ~ 11

Author(s):

G. Schilling ◽

M. Bruweleit ◽

N. Harbeck ◽

C. Thomssen ◽

K. Becker ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1028 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1028-1028 ◽

Cited By ~ 7

Author(s):

Binghe Xu ◽

Jiayu Wang ◽

Qingyuan Zhang ◽

Yunjiang Liu ◽

Ji Feng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Ib ◽

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

10.1158/1538-7445.sabcs15-ot1-03-16 ◽

2016 ◽

Author(s):

JK Litton ◽

JL Blum ◽

Y-H Im ◽

M Martin ◽

L Mina ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Parp Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

International Study ◽

Open Label ◽

Phase 3